Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 18, 2023 - Issue
Submit an article Journal homepage
307
Views
0
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Healthcare Resource Utilization, Cost and Clinical Outcomes in Patients Diagnosed with COPD Initiating Tiotropium Bromide/Olodaterol versus Fluticasone Furoate/Umeclidinium/Vilanterol Based on Exacerbation History

Sanjay Sethi1 Jacobs School of Medicine and Biomedical Sciences, University at Buffalo, Buffalo, NY, USAORCID Iconhttps://orcid.org/0000-0003-0809-7604View further author information
ORCID Icon,
Brendan Clark2 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-1895-0384View further author information
ORCID Icon,
Lindsay GS Bengtson3 Optum Life Sciences, Eden Prairie, MN, USAView further author information
,
Erin K Buysman3 Optum Life Sciences, Eden Prairie, MN, USAView further author information
,
Swetha Palli2 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USAView further author information
,
Andrew Sargent3 Optum Life Sciences, Eden Prairie, MN, USAView further author information
,
Asif Shaikh2 Boehringer Ingelheim Pharmaceuticals, Inc., Ridgefield, CT, USAORCID Iconhttps://orcid.org/0000-0002-5116-9338View further author information
ORCID Icon &
Gary T Ferguson4 Department of Medicine, Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI, USAView further author information
 show all
Pages 625-641 | Received 30 Aug 2022, Accepted 18 Mar 2023, Published online: 19 Apr 2023

References

  • Nici L, Mammen MJ, Charbek E, et al. Pharmacologic management of chronic obstructive pulmonary disease. an official American thoracic society clinical practice guideline. Am J Respir Crit Care Med. 2020;201:e56–e69.
  • Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease; 2022. Available from: https://goldcopd.org/wp-content/uploads/2021/12/GOLD-REPORT-2022-v1.1-22Nov2021_WMV.pdf. Accessed March 21, 2023.
  • Safka KA, Wald J, Wang H, McIvor L, McIvor A. GOLD stage and treatment in COPD: a 500 patient point prevalence study. Chronic Obstr Pulm Dis. 2016;4:45–55. doi:10.15326/jcopdf.4.1.2016.0126
  • Simeone JC, Luthra R, Kaila S, et al. Initiation of triple therapy maintenance treatment among patients with COPD in the US. Int J Chron Obstruct Pulmon Dis. 2017;12:73–83. doi:10.2147/COPD.S122013
  • Li Y, Lim J, Stemkowski S, Kaila S, Renda A, Shaikh A. Initiation of triple therapy maintenance treatment among patients with COPD. Am J Manag Care. 2020;26:e106–e112.
  • Palli SR, Frazer M, DuCharme M, Buikema AR, Anderson AJ, Franchino-Elder J. Differences in Real-world health and economic outcomes among patients with COPD treated with combination tiotropium/olodaterol versus triple therapy. J Manag Care Spec Pharm. 2020;26:1363–1374. doi:10.18553/jmcp.2020.20159
  • Palli SR, Zhou S, Shaikh A, Willey VJ. Effect of compliance with GOLD treatment recommendations on COPD health care resource utilization, cost, and exacerbations among patients with COPD on maintenance therapy. J Manag Care Spec Pharm. 2021;27:625–637. doi:10.18553/jmcp.2021.20390
  • Palli SR, Buikema AR, DuCharme M, Frazer M, Kaila S, Juday T. Costs, exacerbations and pneumonia after initiating combination tiotropium olodaterol versus triple therapy for chronic obstructive pulmonary disease. J Comp Eff Res. 2019;8:1299–1316. doi:10.2217/cer-2019-0101
  • Buhl R, Criee CP, Kardos P, et al. Dual bronchodilation vs triple therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis. 2018;13:2557–2568. doi:10.2147/COPD.S169958
  • Boehringer Ingelheim Pharmaceuticals, Inc. STIOLTO RESPIMAT (tiotropium bromide and olodaterol) inhalation spray for oral inhalation use [prescribing information]. CT, USA: Boehringer Ingelheim Pharmaceuticals, Inc.; 2018. Available from: https://docs.boehringer-ingelheim.com/Prescribing%20Information/PIs/Stiolto%20Respimat/stiolto.pdf. Accessed March 21, 2023.
  • TRELEGY ELLIPTA (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) GlaxoSmithKline, NC 27709. Research Triangle Park; 2022. Available from: https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Trelegy_Ellipta/pdf/TRELEGY-ELLIPTA-PI-PIL-IFU.PDF. Accessed March 21, 2023.
  • U.S. Department of Labor, Bureau of Labor Statistics. Consumer price index. medical care. Series ID: CUUR0000SAM. Washington, DC: U.S. Dept. of Labor, Bureau of Labor Statistics; 2022. Available from: http://data.bls.gov/cgi-bin/surveymost?cu. Accessed January 26, 2022.
  • Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med. 2018;378:1671–1680. doi:10.1056/NEJMoa1713901
  • Lipson DA, Crim C, Criner GJ, et al. Reduction in all-cause mortality with fluticasone furoate/umeclidinium/vilanterol in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2020;201:1508–1516. doi:10.1164/rccm.201911-2207OC
  • Martinez FJ, Rabe KF, Ferguson GT, et al. Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021;185:106509. doi:10.1016/j.rmed.2021.106509

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.